158 related articles for article (PubMed ID: 11369649)
1. Induction of mitochondrial changes in myeloma cells by imexon.
Dvorakova K; Waltmire CN; Payne CM; Tome ME; Briehl MM; Dorr RT
Blood; 2001 Jun; 97(11):3544-51. PubMed ID: 11369649
[TBL] [Abstract][Full Text] [Related]
2. Molecular and cellular characterization of imexon-resistant RPMI8226/I myeloma cells.
Dvorakova K; Payne CM; Tome ME; Briehl MM; Vasquez MA; Waltmire CN; Coon A; Dorr RT
Mol Cancer Ther; 2002 Jan; 1(3):185-95. PubMed ID: 12467213
[TBL] [Abstract][Full Text] [Related]
3. Imexon-induced apoptosis in multiple myeloma tumor cells is caspase-8 dependent.
Evens AM; Prachand S; Shi B; Paniaqua M; Gordon LI; Gartenhaus RB
Clin Cancer Res; 2004 Feb; 10(4):1481-91. PubMed ID: 14977852
[TBL] [Abstract][Full Text] [Related]
4. Induction of oxidative stress and apoptosis in myeloma cells by the aziridine-containing agent imexon.
Dvorakova K; Payne CM; Tome ME; Briehl MM; McClure T; Dorr RT
Biochem Pharmacol; 2000 Sep; 60(6):749-58. PubMed ID: 10930529
[TBL] [Abstract][Full Text] [Related]
5. Correlates of imexon sensitivity in human multiple myeloma cell lines.
Samulitis BK; Landowski TH; Dorr RT
Leuk Lymphoma; 2006 Jan; 47(1):97-109. PubMed ID: 16321833
[TBL] [Abstract][Full Text] [Related]
6. Imexon activates an intrinsic apoptosis pathway in RPMI8226 myeloma cells.
Dvorakova K; Payne CM; Landowski TH; Tome ME; Halperin DS; Dorr RT
Anticancer Drugs; 2002 Nov; 13(10):1031-42. PubMed ID: 12439337
[TBL] [Abstract][Full Text] [Related]
7. Antiproliferative and antitumor activity of the 2-cyanoaziridine compound imexon on tumor cell lines and fresh tumor cells in vitro.
Hersh EM; Gschwind CR; Taylor CW; Dorr RT; Taetle R; Salmon SE
J Natl Cancer Inst; 1992 Aug; 84(16):1238-44. PubMed ID: 1640482
[TBL] [Abstract][Full Text] [Related]
8. Reactive oxygen species generation and mitochondrial dysfunction in the apoptotic response to Bortezomib, a novel proteasome inhibitor, in human H460 non-small cell lung cancer cells.
Ling YH; Liebes L; Zou Y; Perez-Soler R
J Biol Chem; 2003 Sep; 278(36):33714-23. PubMed ID: 12821677
[TBL] [Abstract][Full Text] [Related]
9. Imexon-based combination chemotherapy in A375 human melanoma and RPMI 8226 human myeloma cell lines.
Scott J; Dorr RT; Samulitis B; Landowski TH
Cancer Chemother Pharmacol; 2007 May; 59(6):749-57. PubMed ID: 17333195
[TBL] [Abstract][Full Text] [Related]
10. Implication of mitochondria-derived reactive oxygen species, cytochrome C and caspase-3 in N-(4-hydroxyphenyl)retinamide-induced apoptosis in cervical carcinoma cells.
Suzuki S; Higuchi M; Proske RJ; Oridate N; Hong WK; Lotan R
Oncogene; 1999 Nov; 18(46):6380-7. PubMed ID: 10597238
[TBL] [Abstract][Full Text] [Related]
11. Induction of apoptosis and cell cycle arrest by imexon in human pancreatic cancer cell lines.
Dorr RT; Raymond MA; Landowski TH; Roman NO; Fukushima S
Int J Gastrointest Cancer; 2005; 36(1):15-28. PubMed ID: 16227632
[TBL] [Abstract][Full Text] [Related]
12. The proteasome inhibitor bortezomib promotes mitochondrial injury and apoptosis induced by the small molecule Bcl-2 inhibitor HA14-1 in multiple myeloma cells.
Pei XY; Dai Y; Grant S
Leukemia; 2003 Oct; 17(10):2036-45. PubMed ID: 14513055
[TBL] [Abstract][Full Text] [Related]
13. The small-molecule Bcl-2 inhibitor HA14-1 interacts synergistically with flavopiridol to induce mitochondrial injury and apoptosis in human myeloma cells through a free radical-dependent and Jun NH2-terminal kinase-dependent mechanism.
Pei XY; Dai Y; Grant S
Mol Cancer Ther; 2004 Dec; 3(12):1513-24. PubMed ID: 15634644
[TBL] [Abstract][Full Text] [Related]
14. The antitumor agent imexon activates antioxidant gene expression: evidence for an oxidative stress response.
Baker AF; Landowski T; Dorr R; Tate WR; Gard JM; Tavenner BE; Dragovich T; Coon A; Powis G
Clin Cancer Res; 2007 Jun; 13(11):3388-94. PubMed ID: 17545547
[TBL] [Abstract][Full Text] [Related]
15. Nitroxide TEMPOL impairs mitochondrial function and induces apoptosis in HL60 cells.
Monti E; Supino R; Colleoni M; Costa B; Ravizza R; Gariboldi MB
J Cell Biochem; 2001; 82(2):271-6. PubMed ID: 11527152
[TBL] [Abstract][Full Text] [Related]
16. Involvement of mitochondria and caspase-3 in ET-18-OCH(3)-induced apoptosis of human leukemic cells.
Gajate C; Santos-Beneit AM; Macho A; Lazaro Md; Hernandez-De Rojas A; Modolell M; Muñoz E; Mollinedo F
Int J Cancer; 2000 Apr; 86(2):208-18. PubMed ID: 10738248
[TBL] [Abstract][Full Text] [Related]
17. Anti-tumor activity and mechanism of action for a cyanoaziridine-derivative, AMP423.
Dorr RT; Wisner L; Samulitis BK; Landowski TH; Remers WA
Cancer Chemother Pharmacol; 2012 Apr; 69(4):1039-49. PubMed ID: 22186884
[TBL] [Abstract][Full Text] [Related]
18. The pyridone-annelated isoindigo (5'-Cl) induces apoptosis, dysregulation of mitochondria and formation of ROS in leukemic HL-60 cells.
Saleh AM; Aljada A; El-Abadelah MM; Sabri SS; Zahra JA; Nasr A; Aziz MA
Cell Physiol Biochem; 2015; 35(5):1958-74. PubMed ID: 25871324
[TBL] [Abstract][Full Text] [Related]
19. Induction of apoptosis by sodium selenite in human acute promyelocytic leukemia NB4 cells: involvement of oxidative stress and mitochondria.
Li J; Zuo L; Shen T; Xu CM; Zhang ZN
J Trace Elem Med Biol; 2003; 17(1):19-26. PubMed ID: 12755497
[TBL] [Abstract][Full Text] [Related]
20. Combined phase I/II study of imexon (AOP99.0001) for treatment of relapsed or refractory multiple myeloma.
Moehler TM; Feneberg R; Ho AD; Golenkov AK; Ludwig H; Kropff M; Khuageva NK; Hajda J; von Broen I; Goldschmidt H
Anticancer Drugs; 2010 Aug; 21(7):708-15. PubMed ID: 20571355
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
